Parecoxib could reduce ELMO3 expression and suppress growth and metastasis of lung cancer, which might be a useful chemotherapeutic agent for inhibiting metastasis and recurrence of NSCLC. The gene discussed is ELMO3; the disease is non-small cell lung carcinoma.